BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

BioNTech SENASDAQ: BNTX

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin narrows to -897.8%

Operating margin was -897.8% in Q2 FY2026, down 705.7 pp from a year earlier. On a trailing-twelve-month basis it was -71.8%, down 41.3 pp year over year. Over 3 fiscal years it narrowed by 95.7 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 11 analysts of -73.0% for the fiscal year ending Dec 2026, down from -22.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-897.8%-338.0 pp QoQ
Last fiscal yearDec 2025
-22.6%+25.1 pp YoY
LTMJun 2026
-71.8%-41.3 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-705.7 pp+23.5 pp+729.2 pp
1 year+25.1 pp-50.4 pp-75.5 pp
3 years-95.7 pp-18.0 pp+77.7 pp
5 years+4.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-22.6%
Year-over-year change
+25.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How BNTX compares with its peers on the latest reported figures

  • BNTX's LTM Jun 2026 operating margin of -71.8% is the 8th highest of the 11 companies compared; the peer median is -24.1%.
  • Its year-over-year change of -41.3 pp is the 8th highest of 10, against a peer median of +10.4 pp.
  • Over three fiscal years its change of -95.7 pp compares with a peer median of +18.3 pp.
BNTX Competitors Peer median
Operating Margin for BNTX and competitors
Company Period LTM level YoY 3-year change
CGENCompugen Ltd.LTM Mar 202642.3% +95.9 pp+514.7 pp
GMABGenmab A/SLTM Jun 202632.3% —-9.6 pp
INCYIncyte CorporationLTM Jun 202631.6% +10.4 pp+8.7 pp
TGTXTG Therapeutics, Inc.LTM Sep 202621.5% +2.2 pp+7859.0 pp
IMCRImmunocore Holdings plcLTM Mar 2026-7.6% +6.7 pp+18.3 pp
MGNXMacroGenics, Inc.LTM Mar 2026-40.5% +24.7 pp+32.2 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-60.8% +103.5 pp—
BNTXBioNTech SELTM Jun 2026-71.8% -41.3 pp-95.7 pp
IBRXImmunityBio, Inc.LTM Sep 2026-150.2% +165.7 pp+146148.2 pp
XNCRXencor, Inc.LTM Jun 2026-205.8% -128.2 pp-91.2 pp
IMTXImmatics N.V.LTM Mar 2026-570.3% -528.3 pp-394.4 pp
Peer median (excluding BNTX) -24.1%+10.4 pp+18.3 pp

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.98B17.31B3.82B2.75B2.76B
Cost of Revenue2.91B3B599.8M541.3M616.47M
Gross Profit16.07B14.32B3.22B2.21B2.14B
Gross Margin84.7%82.7%84.3%80.3%77.6%
Research & Development949.2M1.54B1.78B2.25B2.02B
Selling, General & Admin327.2M541.2M557.7M599M698.2M
Operating Expenses781.4M1.67B2.53B3.52B2.76B
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
EBITDA15B13.1B1.38B(367.1M)(628M)
EBITDA Margin79.1%75.7%36.1%-13.3%-22.8%
Operating Income15.28B12.64B690.4M(1.31B)(623.87M)
Operating Margin80.5%73.0%18.1%-47.8%-22.6%
Interest Income1.56M47.37M351.31M0252.24M
Interest Expense5.63M15.82M7.76M13.16M13.64M
Other Income / Expenses(237.4M)311.4M495.7M636.6M(385.46M)
Income Before Tax15.05B12.95B1.19B(677.7M)(1.01B)
Pre-Tax Margin79.3%74.8%31.1%-24.6%-36.6%
Income Tax Expense4.75B3.52B255.8M(12.4M)81.93M
Net Income10.29B9.43B930.3M(665.3M)(1.09B)
Net Margin54.2%54.5%24.4%-24.2%-39.6%
EPS (Basic)43.8738.083.87(2.77)(4.51)
EPS (Diluted)41.2137.093.83(2.77)(4.51)
Weighted Avg Shares244M243.3M240.6M240.4M241.7M
Weighted Avg Shares (Diluted)259.7M249.8M242.7M240.4M241.7M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.